Swedish Drug Co. Meda Pays $3.1B For Rottapharm
Swedish drugmaker Meda AB agreed Thursday to acquire Rottapharm for $3.1 billion, a cash-and-stock deal Meda hopes will create a European pharmaceutical leader offering a strong balance of prescription and consumer...To view the full article, register now.
Already a subscriber? Click here to view full article